The pharmacokinetics of recombinant FXIII (catridecacog) from the MENTOR TM 2 trial to a real-world study: a head-to-head comparison.
Samantha PascaCojutti PierGiorgioFederico Peanull nullPublished in: Journal of thrombosis and thrombolysis (2022)
2, and 33.9 IU/kg in the RW study.